Affiliation:
1. Department of Nephrology Salford Royal hospital Northern Care Alliance NHS foundation trust Salford, Manchester UK
2. Faculty of Biology Medicine and Health Division of cardiovascular medicine The University of Manchester, Oxford Road Manchester UK
3. Department of Nephrology Liverpool university hospitals NHS Foundation Trust Liverpool Merseyside UK
Abstract
AbstractIntroductionWe evaluated the long‐term outcomes of recurrent glomerulonephritis (RGN) using clinical, histopathological, and demographic predictors.MethodsA retrospective cohort study of kidney transplant recipients (KTR) in two renal centers between 2005 and 2020. Clinical and native kidney histological data were analyzed. The risk factors and outcomes of each primary glomerulonephritis subtype were assessed using Cox methods.Result336 recipients with primary glomerulonephritis were analyzed. RGN was diagnosed in 17%, 20%, 25%, and 13% of recipients with IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN) and membranoproliferative glomerulonephritis (MPGN), respectively. Median time to recurrence was shortest in FSGS (.6 years IQR .2‐2.9) and longest in MN (6.3 years IQR 3.3‐8.0) whereas time to graft loss after diagnosis was shortest in MPGN (.3 years IQR .1‐1.7) and longest in IgAN (2.9 year IQR 1.3‐4.3). Recipients with recurrent IgAN were likely to be younger, have higher proteinuria at diagnosis, receive living donor allografts, receive cyclosporine treatment, have a history of acute rejection, and have segmental sclerosis in native glomeruli. Younger age of the donors, higher proteinuria at diagnosis, alemtuzumab, proteinuria within the first 12 months, acute rejection, low baseline eGFR, mesangial proliferation, and IgG and IgA deposits were associated with FSGS recurrence. MPGN recurrence was predicted by lower BMI at transplantation, and crescentic native disease. Death‐censored graft survival at 5‐, 10‐, and 15‐years was 83%, 51%, and 29% in the RGN group and 95%, 93%, and 84%, respectively in the non‐RGN group. Over 15 years, recipients with RGN are nine times more likely than those without RGN to lose their grafts, regardless of donor type, acute rejection, and baseline eGFR. Transplant recipients of related donor allograft were not more likely to have recurrent GN than non‐related donors.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献